FDA Approves First Brain-Penetrating Treatment for Hunter Syndrome in Nearly 20 Years
The FDA has approved Denali’s AVLAYAH, the first brain-penetrating enzyme therapy for Hunter syndrome (MPS II) in nearly 20 years.
NOTRELOAD AI
FDA Greenlights Relacorilant + Nab-Paclitaxel for Hard-to-Treat Ovarian Cancer
The FDA has approved Corcept's relacorilant (Lifyorli) in combination with nab-paclitaxel for platinum-resistant ovarian, fallopian tube, or peritoneal cancer, showing improved survival by several months.
Shares of On Holding Tumble Following CEO Shake-Up
On Holding shares fell after announcing a major leadership shake-up. Co-founders David Allemann and Caspar Coppetti will serve as Co-CEOs from May 1, 2026, as CEO Martin Hoffmann steps down.
BofA Calls Bicara Therapeutics a Buy – Sees Ficerafusp Alfa as Transformative
BofA starts coverage on Bicara Therapeutics with a Buy rating and $35 price target. Ficerafusp alfa shows strong potential in head and neck cancer with clear differentiation over standard care.
Sarepta Hits Early Win With New siRNA Drugs for Rare Muscle Diseases – Beating Rivals on Delivery and Safety
Sarepta just shared first test results for two new medicines aimed at rare muscle diseases FSHD1 and DM1. Early data show the drugs reach high levels in muscle safely, with no serious side effects. Shares jumped.
Why Investors Punished Maze Stock Despite Strong MZE829 Diabetes Data
Maze’s new kidney pill MZE829 cut harmful protein in urine by 35.6% in its Phase 2 trial — including patients with diabetes. Stock still fell 30% as analysts say “don’t compare it to Vertex” but remain very bullish.